Legal 500
Log in or register
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR
  • Rankings

    • Jurisdictions
    • Submissions
    • Future Lawyers
  • Firms & Lawyers

    • Service Providers
    • Barristers’ Sets
    • Networks
    • Interview with…
  • In-House

    • In-House Content
    • GC Powerlist
  • Knowledge Centre

    • Data Products
    • Legal Business
    • Market Intelligence
    • About us

      • Legal 500
      • FAQs
      • Marketing
      • Careers
      • Trust Centre
      • Contact us
  • Comparative Guides
  • Events
  • Legal 500 TV

About us

  • Legal 500
  • FAQs
  • Marketing
  • Careers
  • Trust Centre
  • Contact us
  • Deutschland DE
  • Paris FR

© 2026 Legalease Ltd. All rights reserved

Registered company in England & Wales No. 02427356 VAT GB 321 5727 22

Registered address: 188 Fleet Street, London, EC4A 2AG

  • Legal 500 Trust Centre
  • Contact Us
  • home
  • Market Intelligence
  • Search

7,150 results found

Use advanced search filters to refine your search

2 filters applied

Advanced search filters

Topics
Countries
Contributor

Start typing to add contributors

Content type
Show options
  • Article

    EPA Finalizes Hazardous Waste Pharmaceuticals Rule

    Today U.S. EPA finalized new hazardous waste regulations in its final Management Standards for Hazardous Waste Pharmaceuticals rule.
    United StatesEnvironment
    Troutman Pepper Locke LLP
    Troutman Pepper Locke LLP
  • Article

    2012 Remarkable Year For U.S. Nanotechnology Patenting - Over 4,000 Nanotechnology Applications Published

    The nanotechnology patent filing boom continues. In 2012, the USPTO published 4,098 nanotechnology class 977 applications, which represents a 19.2% increase over last year.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Foley & Lardner LLP
    Foley & Lardner LLP
Article

Accord BioPharma Announces Commercial Launch Of IMULDOSA® (ustekinumab-srlf) Prefilled Syringes In The United States

On August 18, 2025, Accord BioPharma, Inc. ("Accord BioPharma") announced the commercial launch of IMULDOSA® (ustekinumab-srlf), a biosimilar to STELARA® (ustekinumab)...
United StatesFood, Drugs, Healthcare, Life Sciences
Goodwin Procter LLP
Goodwin Procter LLP
  • Article

    AdvaMed, Releases AI White Paper

    AdvaMed, the world's largest medical technology association representing device, diagnostics and digital technology companies, released a white paper that reviews the current landscape of artificial intelligence (AI)-based applications and products in the health care sector, and identifies steps to accelerate the use of AI in medical technologies.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Akin
    Akin
  • Article

    Alteogen's Aflibercept Biosimilar Receives Positive CHMP Opinion

    We previously reported that South Korean biopharmaceutical company Alteogen submitted its Marketing Authorization Application to the European Medicines Agency ("EMA") for ALT-L9...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech And BiosanaPharma Enter Exclusive Global Licensing Agreement For AVT23

    Under the terms of the agreement, Alvotech will receive exclusive global rights for AVT23 and BiosanaPharma will receive an upfront payment and will be eligible for certain tiered royalties.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech and Lotus Enter Agreement for Durvalumab and Emicizumab Biosimilars

    Alvotech and Lotus Pharmaceutical have entered into a strategic licensing and commercialization agreement for two proposed biosimilars targeting major therapeutic markets. The deal encompasses semi-exclusive U.S. rights and exclusive rights across eight Asian markets, with Alvotech retaining development and regulatory responsibilities. Financial terms include potential payments of up to $150 million plus ongoing supply revenue.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech And STADA Launch HUKYNDRA® (Biosimilar Of HUMIRA®) In Europe

    Alvotech and Stada recently announced the launch of HUKYNDRA® to patients in certain European countries, including France, Germany, Finland, and Sweden.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Alvotech Announces Positive Topline Results From Confirmatory Clinical Study For Its Proposed Golimumab Biosimilar

    On April 23, 2024, Alvotech announced "positive topline results from a confirmatory clinical study for AVT05," Alvotech's proposed golimumab biosimilar to Janssen Biotech, Inc.'s...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Amgen Announces Positive Top-Line Results From Phase 3 Study Of Eculizumab Biosimilar

    On August 23, 2022, Amgen announced positive top-line results from a phase 3 study of ABP 959, Amgen's proposed biosimilar to SOLIRIS.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Amneal Achieves Third U.S. Biosimilar Approval With FYLNETRA (pegfilgrastim-pbbk)

    Amneal announced today that the U.S. Food and Drug Administration has approved its Biologics License Application for FYLNETRA™ (pegfilgrastim-pbbk), a biosimilar referencing NEULASTA®.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Amneal Launches Bevacizumab Biosimilar In The United States

    Yesterday, Amneal Pharmaceuticals, Inc. announced the launch of its first biosimilar in the United States: ALYMSYS (bevacizumab-maly), a biosimilar referencing Genentech's AVASTIN product.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Video

    Arnold & Porter Life Sciences: Pharmaceutical Pricing & Contracting (Video)

    Drug pricing is an increasingly complex area that combines business knowledge, the review of difficult and sometimes ambiguous regulations, and the understanding of industry practices.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Arnold & Porter
    Arnold & Porter
  • Article

    Artiva Biotherapeutics Receives FDA Fast Track Designation For AlloNK In Lupus Nephritis

    On February 22, 2024, Artiva announced that the FDA has granted Fast Track designation to Artiva's AlloNK (AB-101) for the treatment of lupus nephritis in combination with rituximab or obinutuzumab...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Biocon Settles With Janssen, Securing U.S. Market Entry Date For Ustekinumab Biosimilar

    On February 29, Biocon Biologics Ltd announced that it signed a settlement and license agreement with Janssen Biotech Inc. and Johnson & Johnson ("J&J") regarding Bmab 1200, Biocon's proposed biosimilar to STELARA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    Biogen And Xbrane Enter Into Worldwide Commercialization And License Agreement For Certolizumab Pegol Biosimilar

    On February 7, 2022, Biogen Inc. and Xbrane Biopharma AB announced that they had entered into a commercialization and license agreement related to Xcimzane, a certolizumab pegol biosimilar referencing CIMZIA.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    BioNTech Acquires Biotheus To Boost Oncology Strategy

    On February 3, 2025, BioNTech SE ("BioNTech") confirmed the completion of its acquisition of biotechnology company Biotheus...
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Article

    BPCIA Lawsuit Against Celltrion And Hospira

    On March 6, 2015, Janssen Biotech, Inc and New York University filed suit against Celltrion Healthcare Co., Ltd., Celltrion, Inc. and Hospira, Inc.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Patterson Belknap Webb & Tyler LLP
    Patterson Belknap Webb & Tyler LLP
  • Article

    CDER And Duke University To Cosponsor Three-Day Training Course For Clinical Investigators

    FDA's CDER announced it will cosponsor a three-day training course on scientific, ethical, and regulatory aspects of clinical trials with Duke University.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Jones Day
    Jones Day
  • Article

    Celltrion And Genuv Partner To Develop Novel Therapeutic Antibodies

    Celltrion and Genuv Inc., a Seoul-based a clinical-stage biotechnology company focused on drug discovery, entered a partnership last week to develop novel therapeutic antibodies using Genuv's SHINE MOUSE platform.
    United StatesFood, Drugs, Healthcare, Life Sciences
    Goodwin Procter LLP
    Goodwin Procter LLP
  • Showing 621–640 of 7150 results

    PreviousNext
    Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics